References
1. Giulino-Roth L, Keller FG, Hodgson DC, Kelly KM. Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. Br J Haematol. 2015;169:647–60.
2. Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol. 2012;157:3–13.
3. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27–37.
4. Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, et al. Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin’s Lymphoma: A Study From the Intergruppo Italiano Linfomi. J Clin Oncol. 2011;29:4227–33.
5. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. J Clin Oncol. 2004;22:1864–71.
6. Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, et al. Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod. 2016;31:263–72.
7. Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patient. Ther Adv Hematol. 2011;2:111–9.
8. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin’s Lymphoma. N Engl J Med. 2012;366:399–408.
9. Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, et al. Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children’s Oncology Group Study AHOD0031. J Clin Oncol. 2014;32:3651–8.
10. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051–9.
11. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, et al. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) Comparative Analysis. Blood. 2015;126:2636–2636.
12. Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden SL, et al. Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood. 2021;137:1449–56.
13. Stieglitz E, Dinh T, Phelps AS, Pampaloni MH, Olshen AB, Robbins E. ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. J Pediatr Hematol Oncol. 2018;40:290–4.
14. Ingley KM, Nadel HR, Potts JE, Wilson DC, Eftekhari A, Deyell RJ. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD. J Pediatr Hematol Oncol. 2020;42:e87–93.
15. Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230–42.
16. Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K, Metz JM, et al. Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma. JCO Clin Cancer Inform. 2018;2:1–10.
17. Chow LML, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, et al. Survival and Late Effects in Children With Hodgkin’s Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation. J Clin Oncol. 2006;24:5735–41.
18. Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, et al. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:3009–17.
19. Kahn JM, Keegan THM, Tao L, Abrahão R, Bleyer A, Viny AD. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016;122:2723–30.
20. Grubb WR, Neboori HJ, Diaz AD, Li H, Kwon D, Panoff J. Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population. Pediatr Blood Cancer. 2016;63:428–35.
Figure Legends
Figure 1 – Event-free survival and overall survival. A: Event-free survival as defined by time to first relapse or last-known follow-up if still in first remission. B: Overall survival, as defined by time to death or to last-known follow-up if still alive. ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine. ABVE-PC: Adriamycin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide
ImageEFSOS